We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanobridges Transport Pro-Metastatic MicroRNAs from Cancer Cells to Surrounding Normal Tissues

By LabMedica International staff writers
Posted on 30 Dec 2015
Scanning electron microscope images revealed that spreading breast cancer cells generated "nanobridges" to connect to surrounding endothelial cells in order to transfect them with pro-metastatic microRNA molecules.

MicroRNAs (miRNAs) are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. More...
With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.

While metastasis is a major cause of mortality and remains an obstacle in the search for a cure for cancer, little is known about metastatic cancer cells and endothelial cross-talk, which occurs at multiple stages during metastasis.

To better understand this process, investigators at Brigham and Women's Hospital (Boston, MA, USA) used scanning electron microscopy (SEM) techniques to observe the growth of a mixture of endothelial cells and metastatic breast cancer cells on a three-dimensional tumor matrix. They found that instead of adhering to themselves to form a sphere, the metastatic breast cancer cells spread out along the model's blood vessels. SEM revealed long, thin tubes (nanobridges) extending outward from the cancer cells to connect them to surrounding normal tissue.

Additional results published in the December 16, 2015, online edition of the journal Nature Communications revealed that contact with cancer cells caused changes in the molecular profiles of some of the normal endothelial cells. The investigators hypothesized that microRNAs were being transferred over the nanobridges into the endothelial cells, and it was found that the transformed endothelial cells had begun to express two microRNAs that had previously been implicated in metastasis.

Some chemotherapeutic agents, such as docetaxel, were shown to disrupt formation of nanobridges in treated cultures, which prevented direct communication between the tumor cells and endothelium. In mice pretreated with this class of pharmacological agent, there was a significant decrease in metastatic tumor burden.

"Metastasis remains a final frontier in the search for a cure for cancer," said senior author Dr. Shiladitya Sengupta, professor of bioengineering at Brigham and Women's Hospital. "For the past five years we have studied how cancer travels to other parts of the body, and what we find is that communication is key. Our study opens up new avenues for exploration and suggests that these nanoscale membrane bridges may represent new therapeutics in managing metastatic breast cancer. We plan to continue searching for and evaluating treatments that take aim at these conduits."

Related Links:

Brigham and Women's Hospital



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.